SUPN

Supernus Pharmaceuticals Inc

SUPN, USA

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

https://www.supernus.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SUPN
stock
SUPN

(SUPN) and the Role of Price-Sensitive Allocations news.stocktradersdaily.com

Read more →
SUPN
stock
SUPN

3 Stocks Under $50 That Concern Us Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$60.5

Analyst Picks

Strong Buy

2

Buy

0

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.54

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-4.30 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.18 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-46.81 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.35

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 108.43% of the total shares of Supernus Pharmaceuticals Inc

1.

BlackRock Inc

(16.7066%)

since

2025/06/30

2.

Vanguard Group Inc

(11.0664%)

since

2025/06/30

3.

Armistice Capital, LLC

(8.5817%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.9391%)

since

2025/08/31

5.

Dimensional Fund Advisors, Inc.

(5.388%)

since

2025/06/30

6.

Macquarie Group Ltd

(4.9259%)

since

2025/06/30

7.

State Street Corp

(3.9387%)

since

2025/06/30

8.

Macquarie Small Cap Core I

(3.4552%)

since

2025/07/31

9.

Vanguard Total Stock Mkt Idx Inv

(3.0038%)

since

2025/07/31

10.

Renaissance Technologies Corp

(2.9521%)

since

2025/06/30

11.

Stephens Inv Mgmt Group LLC

(2.8197%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.496%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(2.3299%)

since

2025/08/31

14.

Loomis, Sayles & Company LP

(2.3146%)

since

2025/06/30

15.

Vanguard Small Cap Index

(2.3006%)

since

2025/07/31

16.

GW&K Investment Management, LLC

(2.2556%)

since

2025/06/30

17.

Stephens SMID Select Growth

(2.0118%)

since

2025/06/30

18.

Polar Capital Holdings PLC

(1.7876%)

since

2025/06/30

19.

American Century Companies Inc

(1.6339%)

since

2025/06/30

20.

Vanguard Explorer Inv

(1.6151%)

since

2025/06/30

21.

Goldman Sachs Group Inc

(1.5986%)

since

2025/06/30

22.

Vanguard Small Cap Value Index Inv

(1.484%)

since

2025/07/31

23.

Aristotle Capital Boston, LLC

(1.4417%)

since

2025/06/30

24.

Sofinnova Ventures

(1.4254%)

since

2025/06/30

25.

Woodline Partners LP

(1.3785%)

since

2025/06/30

26.

Victory Capital Management Inc.

(1.3403%)

since

2025/06/30

27.

Charles Schwab Investment Management Inc

(1.3351%)

since

2025/06/30

28.

Northern Trust Corp

(1.2669%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0746%)

since

2025/07/31

30.

DFA US Small Cap Value I

(1.0275%)

since

2025/07/31

31.

Fidelity Small Cap Index

(0.9648%)

since

2025/06/30

32.

Loomis Sayles Small Cap Growth Instl

(0.9293%)

since

2025/07/31

34.

DFA US Targeted Value I

(0.7966%)

since

2025/07/31

35.

Stephens Small Cap Growth

(0.7799%)

since

2025/06/30

36.

iShares Russell 2000 Value ETF

(0.7764%)

since

2025/08/31

37.

Vanguard Tax-Managed Small Cap Adm

(0.6696%)

since

2025/07/31

38.

Dimensional US Targeted Value ETF

(0.5945%)

since

2025/08/29

39.

Argenta-Fund Longer Life Dynamic R Dis

(0.583%)

since

2025/05/31

40.

Avantis US Small Cap Value ETF

(0.5546%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.41

Latest Release

Date

2025-09-30

EPS Actual

-0.8

EPS Estimate

0.14

EPS Difference

-0.94

Surprise Percent

-671.4286%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.